ANALYSIS OF INFLUENCE ON THE BUDGET OF THE RUSSIAN FEDERATION OF THE USE OF ORAL VINORELBINE FOR THE TREATMENT OF METASTATIC BREAST CANCER
- Authors: Shabalkin P.I1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: No 7 (2018)
- Pages: 71-75
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295479
- ID: 295479
Cite item
Open Access
Access granted
Abstract
Background. Breast cancer (BC) is a serious medical and social problem for society. Treatment of metastatic breast cancer (MBC) involves the appointment of several lines of chemotherapy. Clinical recommendations contain a lot of options for choosing a treatment regimen. Existing limited resources, however, do not always allow using the most effective regimen for treatment of MBC. Objective. Evaluation of the effect of the oral vinorelbine (capsules) on the budget of the Russian Federation in comparison with the most frequently used and comparable in clinical effectiveness parenteral pharmacotherapy regimens for advanced MBC in patients previously treated with anthracyclines and taxanes. Methods. In order to select the optimal therapy for advanced BC, a cost analysis and «budget impact» analysis for oral vinorelbine were performed as compared with intravenous eribulin and ixabepilone. Results. The cost analysis and «budget impact» analysis have shown a positive economic effect from the use of oral vinorelbine as an alternative therapy for advanced BC. As a result of the «budget impact» analysis, suspected budget savings with the replacement of eribulin and ixabepilone on oral vinorelbine is 860,870.2 rubles per patient in a year in comparison with eribulin and 137,615.8 rubles for ixabepilone. Conclusion. The use of oral vinorelbine in the 2nd-3rd line therapy of advanced MBC is reasonable from the position of the healthcare economics.
Keywords
Full Text
About the authors
P. I Shabalkin
N.N. Blokhin National Medical Research Center of Oncology
Email: p.shabalkin@gmail.com
Moscow, Russia
References
- Состояние онкологической помощи населению России в 2015 году/ Под ред. А.Д. КапринА., В.В. Старинского, Г. В. Петровой. М., 2016. С. 234-36.
- Аркадьева Т.В., Давиденко И.С., Розенбаум Л.А., Поддубная И.В. Навельбин в комбинации с доксорубицином в терапии I линии у больных первично диссеминированным и метастатическим раком молочной железы (предварительные данные). Современная онкология. 2000;2:51-4.
- Andrade J., Bines J., Ferrari B., Filho E.A., Lago S., Murad A. Первичное лечение больных местно-распространенным раком молочной железы с повышенной экспрессией HER-2 в еженедельном режиме доцетаксела и герцептина. Современная онкология. 2003;4:140-43.
- Bucher D., Grossi F. Oral Vinorelbine Plus Cisplatin Versus Pemetrexed Plus Cisplatin as First-Line Treatment for Patients with Advanced non- Squamous non- Small Cell Lung Cancer: a Cost Minimization Analysis in Twelve European Countries. Value Health. 2015;18(7):A446.
- Steger G.G., Dominguez A., Dobrovolskaya N., et al. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. Clin. Breast Cancer. 2018;18(1):e41-e47.
- Montagna E., Palazzo A., Maisonneuve P., et al. Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial. Cancer Lett. 2017;400:276-81.
- Cazzaniga M.E., Dionisio M.R., Riva F. Metronomic chemotherapy for advanced breast cancer patients. Cancer Lett. 2017;400:252-58.
- Cazzaniga M.E., Torri V., Riva F., et al. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study Tumori. 2017; 103(1):e4-e8.
- Barni S., Freier B., Garau I., et al. Burden of advanced breast cancer for patients and caregivers in Europe: comparison of two treatment forms of vinorelbine, oral and intravenous. Curr. Med. Res. Opin. 2016;32(11):1807-12.
- Farhat F., Kattan J.G., Ghosn M. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer. Cancer Chemother. Pharmacol. 2016;77(5):1069-77.
- Cinieri S., Chan A., Altundag K., et al. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer. Clin. Breast Cancer. 2017;17(2):91-9.e1.
- Petrelli F., Di Cosimo S., Lonati V., Barni S. Vinorelbine With Capecitabine, an Evergreen Doublet for Advanced Breast Cancer: A Systematic Literature Review and Pooled-Analysis of Phase II-III Studies. Clin. Breast Cancer. 2016;16(5):327-34.
- Плавинский С.Л., Шабалкин П.И. Использование ингибиторa циклин-зависимых киназ 4/6 (палбоциклиб) в терапии гормон-зависимого метастатического рака молочной железы. Анализ затраты- последствия. Сибирский онкологический журнал. 2017;16(4):19-25.
- Приказ Минздрава России от 07.11.2012 № 612н «Об утверждении стандарта оказания специализированной помощи при первично-генерализованных и рецидивных формах злокачественных новообразованиях молочной железы IV стадии - первично; I-IV стадии прогрессирование (системное лекарственное, в том числе химиотерапевтическое, лечение)»
- Тарифное соглашение на оплату медицинской помощи, оказываемой по территориальной программе обязательного медицинского страхования города Москвы на 2017 год, http://www. mgfoms.ru/medicinskie-organizacii/tarifi
Supplementary files
